CD19 and diffuse large B-cell lymphoma: Coltuximab ravtansine (anti-CD19 mAb + microtubule disruptive agent DM4) showed only a moderate efficacy in RR DLBCL in contrast with another CD19 targeting agent—lonca [52,53].